The battle for the brain
Susobhan Sarkar & V Wee Yong
Hotchkiss Brain Institute and Department of Clinical Neurosciences; University of Calgary; Calgary, Canada
Published online: 14 Feb 2014.

To cite this article: Susobhan Sarkar & V Wee Yong (2014) The battle for the brain, OncoImmunology, 3:3, e28047, DOI: 10.4161/onci.28047
To link to this article: http://dx.doi.org/10.4161/onci.28047

It is essential that you check the license status of any given Open and Open Select article to confirm conditions of access and use.
The battle for the brain
Brain tumor-initiating cells vs. microglia/macrophages

Susobhan Sarkar and V Wee Yong*
Hotchkiss Brain Institute and Department of Clinical Neurosciences; University of Calgary; Calgary, Canada

Keywords: innate immunity, microglia, glioma stem cells, amphotericin, reactivation

Brain tumor-initiating cells (BTICs) become less tumorigenic when co-cultured with microglia/macrophages (M/Ms) isolated from subjects not affected by glioma, but not when exposed to the M/Ms of glioma patients. Microglial cells and macrophages from glioma patients, however, can be reactivated by non-toxic doses of amphotericin B to curb the growth of BTICs in vitro and in vivo.

Malignant gliomas, particularly Grade IV glioblastoma, account for 3–5% of all cancer-related deaths. Despite significant advances in multimodal therapeutic approaches, malignant gliomas remain largely untreatable, with median survival time not exceeding 15 mo.1 Glioblastoma is indeed associated with one of the worst 5-y survival rates of all human cancers. The growth of malignant gliomas is maintained by a rare population of cells that proliferate and undergo self-renewal, preserving the original tumor while seed-ing and generating relatively more differentiated lesions. These self-renewing precursors have been variously referred to as glioma stem cells, brain tumor stem cells, glioblastoma-derived cancer stem cells, or brain tumor-initiating cells (BTICs).2

In situ, glioma cells are surrounded by monocytic cells, encompassing both central nervous system (CNS)-resident and tissue-infiltrating cells, such as the microg-lia and tumor-associated macrophages (TAMs), respectively. As it is difficult to differentiate microglial cells from macro-phages in histological sections stained for various myeloid markers, these cells are collectively referred to as microglia/macrophages (M/Ms). A substantial literature has described the interactions between M/Ms and glioma cells. In physiological conditions, M/Ms operate as major antigen-presenting cells in the brain, not only activating T cell-mediated immune responses, but also exerting other immunological functions such as the phagocytic clearance of several threats. However, gliomas appear to suppress the immunological functions of M/Ms,3,4 by producing immunosuppressive molecules such as interleukin-10, transforming growth factor β1 (TGFβ1) and various prostaglandins. Moreover, glioma cells commonly recruit M/Ms to produce growth and angiogenic factors. Nevertheless, there is evidence that M/Ms attempt to counteract the growth of gliomas. M/M-derived factors stimulate indeed the apoptotic demise of differentiated glioma cells in vitro and in vivo.5 Moreover, the microglia of glioma patients can suppress the proliferation of glioma cells in culture upon activation.6 This said, perhaps the most compelling evidence in support of the antineoplastic activity of M/Ms is the increased intracranial growth of gliomas in mice subjected to the genetic ablation of innate immune cells.7 These results suggest that M/Ms can engage in a “battle for the brain” (Fig. 1), although in most cases their activity appears to be co-opted by gliomas. Notably, M/Ms can be polarized to cytotoxic M1 or tumor-promoting M2 cells, depending upon the type of stimulus.8

We recently set out to understand when M/Ms inhibit tumor growth in the course gliomagenesis and when they are co-opted by neoplastic lesions to promote tumor progression. We believed that this information would allow medications that activate M/Ms to be applied with an optimal timing to achieve superior antineo-plastic effects. We found that M/Ms from individuals not affected by glioma, as well as their secretory products, not only reduced the growth of BTICs and their self-renewal in culture, but also caused them to differentiate into cells with characteristics of astrocytes and neurons. This interesting observation encouraged us to conduct in vivo studies. We found that the oncogenic potential of BTICs is significantly reduced if they are exposed to microglia-conditioned medium for 72 h prior to implantation into the murine brain. Thus, one component of the “battle for the brain” involves the inhibition of BTIC growth by M/Ms, demonstrating that these latter cells are capable of exerting an antineoplastic activity. In contrast, M/Ms isolated from glioblastoma patients not only failed to reduce the growth of autologous or heterologous BTICs, but also did not promote their differentiation.

*Correspondence to: V Wee Yong; Email: vyong@ucalgary.ca
Submitted: 01/19/2014; Accepted: 01/29/2014; Published Online: 02/14/2014
Citation: Sarkar S, Yong VW. The battle for the brain: Brain tumor-initiating cells vs. microglia/macrophages. OncoImmunology 2014; 3:e28047
http://dx.doi.org/10.4161/onci.28047
These data clearly demonstrate that the microglia, TAMs and circulating monocytes of glioma patients are deactivated. 

This encouraged us to search for a compound that would reprogram and/or reactivate these mononuclear cells.

We sought to increase the activity of M/Ma using clinically employed drugs. Among 1040 distinct agents of this type, we identified amphotericin B (AmpB) which is primarily used to treat patients with life-threatening fungal infections, as a molecule capable of activating cultured M/Ms to secrete both M1 and M2 cytokines, and enhancing the ability of M/Ms to promote the differentiation of BTICs into cells with astrocytic or neuronal properties. The systemic administration of AmpB reduced the growth of patient-derived BTICs growing orthotopically in SCID-NOD mice and doubled the lifespan of these animals. This effect required M/Ms, as AmpB itself has no direct activity on BTICs and because the depletion of monocytic cells in vivo by clodronate-loaded liposomes abrogated the survival benefit afforded by AmpB. Moreover, The M/M-dependent antineoplastic activity of AmpB was observed in the absence of relevant side effects, and at 10% the serum concentration of AmpB needed to treat patients with fungal infections. This safety margin suggests that AmpB may represent a novel immunotherapeutic approach for patients with gliomas.

When we analyzed brain sections from AmpB-treated mice, we detected a massive activation of M/Ms in the proximity of glioma. Neuro Oncol 2010; 12:1113-25; PMID:20667896; http://dx.doi.org/10.1093/neuonc/noq082

To the best of our knowledge, our findings identify the first FDA-approved medication that has the capacity to reduce the oncogenic potential of BTICs. Our discovery may have a broad utility as the immunological activity of TAMs is compromised in most solid tumors.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References


3. Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. Neuro Oncol 2012; 14:958-78; PMID:22573310; http://dx.doi.org/10.1093/neuroonc/nos116


